Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Worth Seeing!
Transform your wealth with Omega. Exclusive consultation awaits.Schedule Meeting!
Schedule Meeting!
Strides Pharma Science is currently trading at Rs. 331.75, up by 5.15 points or 1.58% from its previous closing of Rs. 326.60 on the BSE.
The scrip opened at Rs. 332.45 and has touched a high and low of Rs. 334.50 and Rs. 329.80 respectively. So far 4512 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 847.45 on 11-Jun-2021 and a 52 week low of Rs. 263.45 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 334.50 and Rs. 296.70 respectively. The current market cap of the company is Rs. 2932.99 crore.
The promoters holding in the company stood at 30.60%, while Institutions and Non-Institutions held 38.48% and 30.92% respectively.
Strides Pharma Science’s step-down wholly owned subsidiary -- Strides Pharma Global Pte, Singapore, has received approval for Ibuprofen Oral Suspension USP, 100 mg/5 mL from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil).
The US market for Ibuprofen Oral Suspension USP, 100 mg/5 mL is approximately $66 million. The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market. The company has 274 cumulative ANDA filings (including recently acquired portfolio from Endo at Chestnut Ridge) with USFDA of which 250 ANDAs have been approved and 24 are pending approval.
The company currently has around 60 commercialized products in the US and has set a target to launch around 20 new products every year from the combined portfolio.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1858.70 |
| Dr. Reddys Lab | 1258.55 |
| Cipla | 1559.20 |
| Lupin | 2198.25 |
| Zydus Lifesciences | 1004.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
